Abstract
Objective: To study the efficacy, safety, and incidence of BtxA antibody formation with repeated treatments with BtxA in post-stroke upper limb muscle spasticity.
Methods: The study was a prospective open label trial. Patients with established post-stroke upper limb spasticity received 1000 units of BtxA (Dysport) into five muscles of the affected arm on study entry. Treatment was repeated every 12, 16, or 20 weeks as clinically indicated. Each patient received a total of three treatment cycles. Efficacy of treatment was assessed using the Modified Ashworth Scale. Patients were assessed on study entry and on week 4 and 12 of each treatment cycle for all safety and efficacy parameters. Blood samples for BtxA antibody assay were taken at baseline and on completion of the trial.
Results: Fifty one patients were recruited and 41 of them completed the study. Improvement from the cycle one baseline was observed in all the outcome measures. Mild to moderately severe treatment related adverse events were reported in 24% of cases. There were no serious adverse events. No BtxA antibodies were detected.
Conclusion: BtxA at a dose of 1000 units Dysport was efficacious in the symptomatic treatment of post-stroke upper limb spasticity. The study suggests that this effect can be maintained with repeated injections for up to at least three treatment cycles, with duration of effect per cycle of between 12 and 20 weeks. BtxA was safe in the dose used in this study and did not induce the formation of detectable levels of neutralising BtxA antibodies.
Full Text
The Full Text of this article is available as a PDF (60.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aho K., Harmsen P., Hatano S., Marquardsen J., Smirnov V. E., Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58(1):113–130. [PMC free article] [PubMed] [Google Scholar]
- Bakheit A. M., Thilmann A. F., Ward A. B., Poewe W., Wissel J., Muller J., Benecke R., Collin C., Muller F., Ward C. D. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000 Oct;31(10):2402–2406. doi: 10.1161/01.str.31.10.2402. [DOI] [PubMed] [Google Scholar]
- Bhakta B. B., Cozens J. A., Chamberlain M. A., Bamford J. M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):217–221. doi: 10.1136/jnnp.69.2.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bohannon R. W., Smith M. B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206–207. doi: 10.1093/ptj/67.2.206. [DOI] [PubMed] [Google Scholar]
- Brashear Allison, Gordon Mark F., Elovic Elie, Kassicieh V. Daniel, Marciniak Christina, Do Mai, Lee Chia-Ho, Jenkins Stephen, Turkel Catherine, Botox Post-Stroke Spasticity Study Group Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8;347(6):395–400. doi: 10.1056/NEJMoa011892. [DOI] [PubMed] [Google Scholar]
- Emanuel E. J., Miller F. G. The ethics of placebo-controlled trials--a middle ground. N Engl J Med. 2001 Sep 20;345(12):915–919. doi: 10.1056/NEJM200109203451211. [DOI] [PubMed] [Google Scholar]
- Hanna P. A., Jankovic J., Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May;66(5):612–616. doi: 10.1136/jnnp.66.5.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hyman N., Barnes M., Bhakta B., Cozens A., Bakheit M., Kreczy-Kleedorfer B., Poewe W., Wissel J., Bain P., Glickman S. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):707–712. doi: 10.1136/jnnp.68.6.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koman L. A., Mooney J. F., 3rd, Smith B. P., Walker F., Leon J. M. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop. 2000 Jan-Feb;20(1):108–115. [PubMed] [Google Scholar]
- Simpson D. M., Alexander D. N., O'Brien C. F., Tagliati M., Aswad A. S., Leon J. M., Gibson J., Mordaunt J. M., Monaghan E. P. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996 May;46(5):1306–1310. doi: 10.1212/wnl.46.5.1306. [DOI] [PubMed] [Google Scholar]
- Zuber M., Sebald M., Bathien N., de Recondo J., Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology. 1993 Sep;43(9):1715–1718. doi: 10.1212/wnl.43.9.1715. [DOI] [PubMed] [Google Scholar]
- de Paiva A., Meunier F. A., Molgó J., Aoki K. R., Dolly J. O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3200–3205. doi: 10.1073/pnas.96.6.3200. [DOI] [PMC free article] [PubMed] [Google Scholar]